Sandrine DABERNAT

Sandrine Dabernat obtained her PhD in biological and medical sciences in 1998. She was interested in the physiological and pathological roles of members of the nm23 gene family, with transgenic mouse models. She completed her doctoral training as a postdoctoral fellow at Scripps Research Institute in La Jolla (USA) for 3 years, studying pancreatic stem cells. She became Associate Professor in Cell Biology, with a position of biologist in the department of Biochemistry, at Bordeaux university hospital in 2003. In 2018, she obtained full professorship. Since 2015, she has been coordinating a group that she has created in team 1 "biotherapies" of the Inserm 1035 unit, led by Prof. François Moreau-Gaudry. This group gathers clinicians working in digestive surgery and radiotherapy of Bordeaux university hospital with the biologists of basic research. In 2015, she participated in the creation of the AFRCP. She created and administrates AFRCP website. Her group is looking for ways to increase pancreatic ductal adenocarcinomas sensitivity to current available conventional treatments and the causes of their resistance to treatment. In particular, bioactive compounds of the food induce a strong oxidative stress in tumor cells, making their elimination more efficient, especially in combination with chemotherapy. The impact of these combinations of bioactive compounds with radiotherapy is currently being published. New resistance targets by large-scale functional analysis using the CRISPR / CAS9 genome editing method is ongoing. A translational project to evaluate the possibility of using diagnostic methods and pancreatic cancer monitoring by liquid biopsy (Program PANC-CTC, circulating tumor cells and circulating exosomes, NCT03032913), offers exciting possibility to improve diagnosis of pancreatic cancer. Induced pluripotent stem cells (iPSCs) are used to evaluate the impact of extracellular vesicles of tumor origin on the fate of healthy human stem cells. Finally, prognostic markers of early post-surgery mortality of patients with resectable PDAC are sought by proteomic methods.

Vendrely V, Peuchant E, Buscail E, Moranvillier I, Rousseau B, Bedel A, Brillac A, de Verneuil H, Moreau-Gaudry F, Dabernat S. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Lett. 2017 Apr1;390:91-102
Peuchant E, Bats ML, Moranvillier I, Lepoivre M, Guitton J, Wendum D, Lacombe ML, Moreau-Gaudry F, Boissan M, Dabernat S. Metastasis suppressor NM23 limits oxidative stress in mammals by preventing activation of stress-activated protein kinases/JNKs through its nucleoside diphosphate kinase activity. FASEB J. 2017 Apr;31(4):1531-1546.

A Bedel, F Beliveau, I Lamrissi-Garcia, I Moranvillier, B Rousseau, V Guyonnet-Dupérat, H de Verneuil, F Moreau-Gaudry, S Dabernat : Preventing pluripotent cell teratoma in regenerative medicine applied to haematology disorders Stem Cells Transl Med. 2016 Sep 7
Lafitte M, Rousseau B, Moranvillier I, Taillepierre M, Peuchant E, Guyonnet-Dupérat V, Bedel A, Dubus P, de Verneuil H, Moreau-Gaudry F*, Dabernat S*. In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer. 2012 Oct 22;11:81
Arnaud-Dabernat S, Kritzik M, Kayali AG, Zhang YQ, Liu G, Ungles C, Sarvetnick N. FGFR3 is a negative regulator of the expansion of pancreatic epithelial cells. Diabetes. 2007 Jan;56(1):96-106.

Top